Adamis Pharmaceuticals Corp (NASDAQ:ADMP) CFO Robert O. Hopkins sold 8,900 shares of the firm’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $2.30, for a total transaction of $20,470.00. Following the transaction, the chief financial officer now directly owns 347,907 shares of the company’s stock, valued at $800,186.10. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
ADMP traded down $0.12 during trading on Friday, reaching $2.14. 423,531 shares of the company’s stock were exchanged, compared to its average volume of 407,582. Adamis Pharmaceuticals Corp has a 1 year low of $2.01 and a 1 year high of $5.10. The firm has a market capitalization of $104.09 million, a PE ratio of -2.14 and a beta of 1.45.
A number of equities analysts have issued reports on the stock. Maxim Group set a $10.00 price target on shares of Adamis Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday. Zacks Investment Research lowered shares of Adamis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, January 14th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $5.56.
Institutional investors and hedge funds have recently bought and sold shares of the business. Jane Street Group LLC purchased a new position in Adamis Pharmaceuticals during the 4th quarter worth approximately $31,000. Cambridge Investment Research Advisors Inc. purchased a new position in shares of Adamis Pharmaceuticals during the 4th quarter valued at approximately $36,000. Oppenheimer & Co. Inc. purchased a new position in shares of Adamis Pharmaceuticals during the 4th quarter valued at approximately $38,000. Barclays PLC purchased a new position in shares of Adamis Pharmaceuticals during the 4th quarter valued at approximately $110,000. Finally, Raymond James & Associates increased its holdings in shares of Adamis Pharmaceuticals by 56.5% during the 4th quarter. Raymond James & Associates now owns 49,596 shares of the specialty pharmaceutical company’s stock valued at $112,000 after purchasing an additional 17,900 shares in the last quarter. 17.60% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Adamis Pharmaceuticals Corp (ADMP) CFO Robert O. Hopkins Sells 8,900 Shares” was originally posted by Zolmax and is the property of of Zolmax. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://zolmax.com/investing/adamis-pharmaceuticals-corp-admp-cfo-robert-o-hopkins-sells-8900-shares/2983519.html.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
Featured Story: Compound Interest
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.